Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways.
Saved in:
| Title: | Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways. |
|---|---|
| Authors: | Kunishima A; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Shimizu T; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Takimoto T; Department of Data Science, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan., Sagara A; Department of Pharmacy, Japanese Red Cross Medical Center, Shibuya, Tokyo 150‑8935, Japan., Nobusue H; Department of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan., Hasuwa H; Department of Collaborative Research Resources (Laboratory Animal Center), Keio University School of Medicine, Shinjuku, Tokyo 160‑8582, Japan., Hasegawa S; Department of Environmental Health Sciences, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Tamaoki Y; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Miyake H; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Fukuchi Y; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan., Saya H; Department of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan., Muto A; Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan. |
| Source: | Oncology reports [Oncol Rep] 2026 May; Vol. 55 (5). Date of Electronic Publication: 2026 Mar 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1791-2431 |
|---|---|
| DOI: | 10.3892/or.2026.9099 |
